AN EXTENSIVE REVIEW ON PRASUGREL

  • GV Nagaraju Department of Pharmacy Practice, Koringa College of Pharmacy, Kakinada, A.P, India
  • SN Subrahmanyam Department of Pharmacy Practice, Koringa College of Pharmacy, Kakinada, A.P, India
  • GV Pavan Kumar Department of Pharmacy Practice, Koringa College of Pharmacy, Kakinada, A.P, India

Abstract

In an attempt prasugrel increase in the overall use of this medication comparing to the anti thembolytics like heparin and wararin, with less patients complaints includes side effects a significant portion of patients receiving the medication for off label indications. More importantly, this agent is used in a substantial number of patients with known contraindications. Prasugrel are more intense platelet inhibition confirmed by the observation of highest percentage of minor or moderate bleeding among patients taking prasugrel, although there was no significant increase in the rate of severe, major, or life-threatening bleeding.


Keywords: prasugrel, thembolytics, wararin, heparin

Downloads

Download data is not yet available.

Author Biographies

GV Nagaraju, Department of Pharmacy Practice, Koringa College of Pharmacy, Kakinada, A.P, India

Department of Pharmacy Practice, Koringa College of Pharmacy, Kakinada, A.P, India

SN Subrahmanyam, Department of Pharmacy Practice, Koringa College of Pharmacy, Kakinada, A.P, India

Department of Pharmacy Practice, Koringa College of Pharmacy, Kakinada, A.P, India

GV Pavan Kumar, Department of Pharmacy Practice, Koringa College of Pharmacy, Kakinada, A.P, India

Department of Pharmacy Practice, Koringa College of Pharmacy, Kakinada, A.P, India

References

1. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357:2001–2015.
2. Wiviott SD, Trenk D, Frelinger AL, O’Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E; PRINCIPLETIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007; 116:2923–2932.
3. Wright R, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger EM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011; 57:1920–1959.
4. Effient (prasugrel) tablets: package insert. Indianapolis, IN: Eli Lilly and Company, 2010.
5. Gurm HS, Smith DE, Collins JS, Share D, Riba A, Carter AJ, LaLonde T, Kline-Rogers E, O’Donnell M, Changezi H, Zughaib M, Safian R, Moscucci M; Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol. 2008; 51:529–535.
6. Kline-Rogers E, Share D, Bondie D, Rogers B, Karavite D, Kanten S, Wren P, Bodurka C, Fisk C, McGinnity J, Wright S, Fox S, Eagle KA,Moscucci M; Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Development of a multicenter interventional cardiology
7. database: the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) experience. J Interv Cardiol. 2002; 15:387–392.
8. Moscucci M, Share D, Kline-Rogers E, O’Donnell M, Maxwell-Eward A, Meengs WL, Clark VL, Kraft P, De Franco AC, Chambers JL, Patel K, McGinnity JG, Eagle KA; Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) collaborative quality
9. Anderson JL, Adams CD, Antman EM, et al.2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/ non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: e179–347.
10. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent STsegment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:2999–3054.
11. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494–502.
12. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin.
13. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011; 32:2999-3054
14. Chan MY, Mahaffey KW, Sun LJ, et al. Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. JACC Cardiovasc Interv 2008; 1:369-378[Erratum, JACC Cardiovasc Interv 2008; 1:600-1.]
15. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022307.
16. Www.Micromex.Com
Statistics
24 Views | 74 Downloads
How to Cite
Nagaraju, G., Subrahmanyam, S., & Pavan Kumar, G. (2018). AN EXTENSIVE REVIEW ON PRASUGREL. Journal of Drug Delivery and Therapeutics, 8(5), 113-114. https://doi.org/10.22270/jddt.v8i5.1897